What is the half-life of P21 (Cerebrolysin-derived)?

P21 (Cerebrolysin-derived) has a half-life of Unknown, which is why it's typically administered As needed for optimal therapeutic effect.

How do I reconstitute P21 (Cerebrolysin-derived)?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

What is the half-life of P21 (Cerebrolysin-derived)?

P21 (Cerebrolysin-derived) has a half-life of Unknown, which is why it's typically administered As needed for optimal therapeutic effect.

How do I reconstitute P21 (Cerebrolysin-derived)?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Healing & Recovery

Preclinical

P21 (Cerebrolysin-derived)

Also known as: P021, P21 peptide, Cerebrolysin-derived P21

Overview

Key Facts

Primary Goal: Research and therapeutic applications of P21 (Cerebrolysin-derived)

Mimics the neurotrophic activity of CNTF by engaging the CNTF receptor alpha/gp130/LIF receptor complex. Inhibits glycogen synthase kinase-3 beta (GSK-3beta), reducing tau hyperphosphorylation.

Dosing Information

Half-Life

~2-4 hours (estimated from animal studies)

Typical Dose

500–1500 mcg

Frequency

once daily

Cycle Length

4-12 weeks

Administration Routes:

subcutaneous

Benefits

Promotes hippocampal neurogenesis in animal models
Reduces tau hyperphosphorylation associated with Alzheimer's pathology
Enhances synaptic plasticity and dendritic branching
Blood-brain barrier permeable unlike parent protein CNTF
Improved spatial learning and memory in aged rodents

Side Effects

Very limited human safety datauncommonmild

Mild nasal irritation with intranasal useuncommonmild

Occasional lethargy during initial dosinguncommonmild

Theoretical immune modulation effects from CNTF pathway activationuncommonmild

Mechanism of Action

Mimics the neurotrophic activity of CNTF by engaging the CNTF receptor alpha/gp130/LIF receptor complex

Inhibits glycogen synthase kinase-3 beta (GSK-3beta), reducing tau hyperphosphorylation

Stimulates dentate gyrus neurogenesis by promoting neural progenitor cell proliferation and differentiation

Lacks the mitogenic properties of full-length CNTF, reducing proliferative risk

Contraindications

Do not use this peptide if any of the following apply:

Pregnancy or breastfeeding
No established human safety profile — research use only
Active CNS infections or inflammatory conditions

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Preclinical

P21 was developed by Dr. Khalid Iqbal and colleagues at the New York State Institute for Basic Research in Developmental Disabilities. Published studies in Neurobiology of Ageing (2011, 2013) demonstrated that P21 administration rescued cognitive deficits in Alzheimer's disease mouse models by promoting neurogenesis and reducing tau pathology. The peptide increased hippocampal neurogenesis by approximately 40-60% in aged mice and significantly improved performance in Morris water maze tests. It remains preclinical with no human trials completed.

Frequently Asked Questions

Common questions about P21 (Cerebrolysin-derived)

UK-Specific Information

Exclusive data points and guidance for UK residents using P21 (Cerebrolysin-derived)

UK Lab Testing

Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)

Generate a trackable link to share this peptide information on TikTok